Mesker WE - Search Results

1

The value of additional bevacizumab in patients with high-risk stroma-high colon cancer. A study within the QUASAR2 trial, an open-label randomized phase 3 trial.

Huijbers A, van Pelt GW, Kerr RS, Johnstone EC, Tollenaar RAEM, Kerr DJ, Mesker WE. Huijbers A, et al. Among authors: mesker we. J Surg Oncol. 2018 Apr;117(5):1043-1048. doi: 10.1002/jso.24998. Epub 2018 Feb 15. J Surg Oncol. 2018. PMID: 29448309 Clinical Trial.

2

Automated analysis of multiple sections for the detection of occult cells in lymph nodes.

Mesker WE, Doekhie FS, Vrolijk H, Keyzer R, Sloos WC, Morreau H, O'Kelly PS, de Bock GH, Tollenaar RA, Tanke HJ. Mesker WE, et al. Clin Cancer Res. 2003 Oct 15;9(13):4826-34. Clin Cancer Res. 2003. PMID: 14581354

3

Supervised automated microscopy increases sensitivity and efficiency of detection of sentinel node micrometastases in patients with breast cancer.

Mesker WE, Torrenga H, Sloos WC, Vrolijk H, Tollenaar RA, de Bruin PC, van Diest PJ, Tanke HJ. Mesker WE, et al. J Clin Pathol. 2004 Sep;57(9):960-4. doi: 10.1136/jcp.2004.017368. J Clin Pathol. 2004. PMID: 15333658 Free PMC article.

4

The feasibility and reliability of sentinel node mapping in colorectal cancer.

Doekhie FS, Peeters KC, Kuppen PJ, Mesker WE, Tanke HJ, Morreau H, van de Velde CJ, Tollenaar RA. Doekhie FS, et al. Among authors: mesker we. Eur J Surg Oncol. 2005 Oct;31(8):854-62. doi: 10.1016/j.ejso.2005.05.011. Eur J Surg Oncol. 2005. PMID: 16005598 Review.

5

Clinical relevance of occult tumor cells in lymph nodes from gastric cancer patients.

Doekhie FS, Mesker WE, van Krieken JH, Kok NF, Hartgrink HH, Kranenbarg EK, Putter H, Kuppen PJ, Tanke HJ, Tollenaar RA, van de Velde CJ. Doekhie FS, et al. Among authors: mesker we. Am J Surg Pathol. 2005 Sep;29(9):1135-44. doi: 10.1097/01.pas.0000160439.38770.cb. Am J Surg Pathol. 2005. PMID: 16096401

6

Prognostic relevance of occult tumour cells in lymph nodes in colorectal cancer.

Doekhie FS, Kuppen PJ, Peeters KC, Mesker WE, van Soest RA, Morreau H, van de Velde CJ, Tanke HJ, Tollenaar RA. Doekhie FS, et al. Among authors: mesker we. Eur J Surg Oncol. 2006 Apr;32(3):253-8. doi: 10.1016/j.ejso.2005.10.010. Epub 2006 Jan 18. Eur J Surg Oncol. 2006. PMID: 16412600 Review.

7

Detection of tumor cells in bone marrow, peripheral blood and lymph nodes by automated imaging devices.

Mesker WE, Vrolijk H, Sloos WC, Tollenaar RA, Tanke HJ. Mesker WE, et al. Cell Oncol. 2006;28(4):141-50. doi: 10.1155/2006/610562. Cell Oncol. 2006. PMID: 16988469 Free PMC article. Review.

8

The carcinoma-stromal ratio of colon carcinoma is an independent factor for survival compared to lymph node status and tumor stage.

Mesker WE, Junggeburt JM, Szuhai K, de Heer P, Morreau H, Tanke HJ, Tollenaar RA. Mesker WE, et al. Cell Oncol. 2007;29(5):387-98. doi: 10.1155/2007/175276. Cell Oncol. 2007. PMID: 17726261 Free PMC article.

9

Nuclear localization of CXCR4 determines prognosis for colorectal cancer patients.

Speetjens FM, Liefers GJ, Korbee CJ, Mesker WE, van de Velde CJ, van Vlierberghe RL, Morreau H, Tollenaar RA, Kuppen PJ. Speetjens FM, et al. Among authors: mesker we. Cancer Microenviron. 2009 Dec;2(1):1-7. doi: 10.1007/s12307-008-0016-1. Epub 2008 Dec 11. Cancer Microenviron. 2009. PMID: 19308676 Free PMC article.

10

Presence of a high amount of stroma and downregulation of SMAD4 predict for worse survival for stage I-II colon cancer patients.

Mesker WE, Liefers GJ, Junggeburt JM, van Pelt GW, Alberici P, Kuppen PJ, Miranda NF, van Leeuwen KA, Morreau H, Szuhai K, Tollenaar RA, Tanke HJ. Mesker WE, et al. Cell Oncol. 2009;31(3):169-78. doi: 10.3233/CLO-2009-0478. Cell Oncol. 2009. PMID: 19478385 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

144 results

Search Page